Kiniksa Pharmaceuticals International
KNSA
77.96
+0.87
+1.13%
Kiniksa Pharmaceuticals International
US · KNSA
#1938 by market cap
Listed 2018
77.96
+0.87
+1.13%
Live - 5344 symbols - heartbeat 83s ago
· 2026-10-08 07:58
Pre-market
77.96
0.00%
After-hours
78.50
+0.69%
- Market cap
- 6.08B
- P/E (TTM)i
- 78.75
- P/Bi
- 9.30
- EPSi
- 0.75
- Div yieldi
- 0.00%
- 52W posi
- 90%
Reader sentiment
Are you bullish or bearish on KNSA?
Anonymous reader poll. Unscientific, not investment advice.
About Kiniksa Pharmaceuticals International
Kiniksa Pharmaceuticals International Plc is a commercial-stage biopharmaceutical company. It engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. The company was founded on April 9, 2024 and is headquartered in London, United Kingdom.
- Founded
- 2024
- CEO
- Mr. Sanj K. Patel
- Employees
- 366
- Headquarters
- London, Greater London, United Kingdom of Great Britain and Northern Ireland (the)
- Fiscal year end
- 12-31
- Website
- kiniksa.com
Company profile
- Exchange
- US
- Symbol
- KNSA
- Market-cap rank
- #1938
- Listing date
- 2018-05-24
- Market cap
- 6.08B
- Float cap
- 3.11B
- Shares out
- 78.02M
- Float shares
- 39.86M
Sectors & themes
Drug Manufacturers - Specialty & Generic
Fractional Shares JP
Quote time 2026-10-08 07:58:36 · For reference only, not investment advice and not tailored to your situation.